 |
Letzte Umfrage
|
|
Welches Angebot von migraeneinformation.de schätzen Sie besonders?
|
| Forum | |  | 84,9% | | News | | | 83,6% | | Umfragen | | | 27,4% | | Termine | | | 19,2% | | Links | | | 11,0% | | Infos zu Medikam. | | | 26,0% | | Infos zu Ernährung | | | 71,2% | | Infos zu Therapien | | | 27,4% | | Online-Tests | | | 43,8% | | Migräne-Kalender | | | 20,5% | |
|
|
Migräne-Wirksamkeit von Botulinium A (Botox) nicht nachgewiesen [Pharma]
16 Jun 06
 |
Allerdings profitieren Patienten mit täglichen chronischen Kopfschmerzen von der Anwendung |
Die Studie reviewt die vorliegenden Untersuchungen zur Wirksamkeit von Botulinium A (Botox) bei Kopfschmerzen und kommt zu dem Schluss, dass eine Wirksamkeit bei idiopatischen Kopfschmerzen nicht nachgewiesen ist. Allerdings scheinen Patienten mit chronischen täglichen Kopfschmerzen von der Anwendung zu profitieren.
Abstract:
Status on the use of botulinum toxin for headache disorders
PURPOSE OF REVIEW: Reports and studies on botulinum toxin A in headache treatment are increasing. The studies available from reference systems and published congress contributions on the prophylactic treatment of idiopathic and symptomatic headache with botulinum toxin were analyzed with respect to the study design, the headache diagnosis, and the significance of results. RECENT FINDINGS: For the prophylactic treatment of tension-type headache and migraine, no sufficient positive evidence for a treatment with botulinum toxin A is obtained from randomized, double-blind, and placebo-controlled trials to date. For the treatment of chronic daily headache (including medication overuse headache), there is inconsistent positive evidence for subgroups (e.g. patients without other prophylactic treatment). SUMMARY: The majority of double-blind and placebo-controlled studies do not confirm the assumption that botulinum toxin A is efficacious in the treatment of idiopathic headache disorders. It is possible that subgroups of patients with chronic daily headache benefit from a long-term treatment with this substance. Future clinical trials should focus on these defined patient groups.
Evers S. Status on the use of botulinum toxin for headache disorders. Curr Opin Neurol. 2006 Jun;19(3):310-5.
Weitere Infos finden sich hier.
|
Kommentare (0)
©migraeneinformation.de 2004 - 2019
|
|
|
|
|
Montag, 25. März 2019 |
|
|
|
 Das Wetter für
Frankfurt am Main |
|
|
| Migräne-Blog |
| März 2019 |
| Mo |
Di |
Mi |
Do |
Fr |
Sa |
So |
KW |
| |
|
|
|
01 |
02 |
03 |
9. |
| 04 |
05 |
06 |
07 |
08 |
09 |
10 |
10. |
| 11 |
12 |
13 |
14 |
15 |
16 |
17 |
11. |
| 18 |
19 |
20 |
21 |
22 |
23 |
24 |
12. |
| 25 |
26 |
27 |
28 |
29 |
30 |
31 |
13. |
| Februar |
|
|
|
|
|
